118 related articles for article (PubMed ID: 9920288)
1. Metabolism of antitumor acylfulvene by rat liver cytosol.
McMorris TC; Elayadi AN; Yu J; Kelner MJ
Biochem Pharmacol; 1999 Jan; 57(1):83-8. PubMed ID: 9920288
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol.
McMorris TC; Elayadi AN; Yu J; Hu Y; Kelner MJ
Drug Metab Dispos; 1999 Sep; 27(9):983-5. PubMed ID: 10460795
[TBL] [Abstract][Full Text] [Related]
3. Acylfulvenes, a new class of potent antitumor agents.
McMorris TC; Kelner MJ; Wang W; Diaz MA; Estes LA; Taetle R
Experientia; 1996 Jan; 52(1):75-80. PubMed ID: 8575564
[TBL] [Abstract][Full Text] [Related]
4. Sulfotransferase-independent genotoxicity of illudin S and its acylfulvene derivatives in bacterial and mammalian cells.
Glatt H; Pietsch KE; Sturla SJ; Meinl W
Arch Toxicol; 2014 Jan; 88(1):161-9. PubMed ID: 23881331
[TBL] [Abstract][Full Text] [Related]
5. Characterization of acylfulvene histiospecific toxicity in human tumor cell lines.
Kelner MJ; McMorris TC; Montoya MA; Estes L; Uglik SF; Rutherford M; Samson KM; Bagnell RD; Taetle R
Cancer Chemother Pharmacol; 1998; 41(3):237-42. PubMed ID: 9443641
[TBL] [Abstract][Full Text] [Related]
6. Quantification of acylfulvene- and illudin S-DNA adducts in cells with variable bioactivation capacities.
Pietsch KE; van Midwoud PM; Villalta PW; Sturla SJ
Chem Res Toxicol; 2013 Jan; 26(1):146-55. PubMed ID: 23227857
[TBL] [Abstract][Full Text] [Related]
7. Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity.
Gong J; Neels JF; Yu X; Kensler TW; Peterson LA; Sturla SJ
J Med Chem; 2006 Apr; 49(8):2593-9. PubMed ID: 16610802
[TBL] [Abstract][Full Text] [Related]
8. Profiling patterns of glutathione reductase inhibition by the natural product illudin S and its acylfulvene analogues.
Liu X; Sturla SJ
Mol Biosyst; 2009 Sep; 5(9):1013-24. PubMed ID: 19668867
[TBL] [Abstract][Full Text] [Related]
9. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.
Kelner MJ; McMorris TC; Montoya MA; Estes L; Uglik SF; Rutherford M; Samson KM; Bagnell RD; Taetle R
Cancer Chemother Pharmacol; 1999; 44(3):235-40. PubMed ID: 10453725
[TBL] [Abstract][Full Text] [Related]
10. Chemical and enzymatic reductive activation of acylfulvene to isomeric cytotoxic reactive intermediates.
Pietsch KE; Neels JF; Yu X; Gong J; Sturla SJ
Chem Res Toxicol; 2011 Nov; 24(11):2044-54. PubMed ID: 21939268
[TBL] [Abstract][Full Text] [Related]
11. (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties.
McMorris TC; Kelner MJ; Wang W; Yu J; Estes LA; Taetle R
J Nat Prod; 1996 Sep; 59(9):896-9. PubMed ID: 8864242
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells.
Kelner MJ; McMorris TC; Montoya MA; Estes L; Rutherford M; Samson KM; Taetle R
Cancer Chemother Pharmacol; 1997; 40(1):65-71. PubMed ID: 9137532
[TBL] [Abstract][Full Text] [Related]
13. On the mechanism of toxicity of illudins: the role of glutathione.
McMorris TC; Kelner MJ; Wang W; Moon S; Taetle R
Chem Res Toxicol; 1990; 3(6):574-9. PubMed ID: 2103329
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity studies of urea, carbamate, and sulfonamide derivatives of acylfulvene.
McMorris TC; Chimmani R; Alisala K; Staake MD; Banda G; Kelner MJ
J Med Chem; 2010 Feb; 53(3):1109-16. PubMed ID: 20067264
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship studies of illudins: analogues possessing a spiro-cyclobutane ring.
McMorris TC; Cong Q; Kelner MJ
J Org Chem; 2003 Dec; 68(25):9648-53. PubMed ID: 14656090
[TBL] [Abstract][Full Text] [Related]
16. HPLC determination of a new anticancer agent (acylfulvene) in serum.
Brandsteterová E; Kelner MJ; McMorris TC; Estes L; Bagnell R; Montoya M
Neoplasma; 1992; 39(6):369-73. PubMed ID: 1491727
[TBL] [Abstract][Full Text] [Related]
17. Metabolism by rat liver cytosol of illudin S, a toxic substance of Lampteromyces japonicus. II. Characterization of illudin S-metabolizing enzyme.
Tanaka K; Inoue T; Kadota S; Kikuchi T
Xenobiotica; 1992 Jan; 22(1):33-9. PubMed ID: 1377439
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells.
Kelner MJ; McMorris TC; Estes L; Starr RJ; Rutherford M; Montoya M; Samson KM; Taetle R
Cancer Res; 1995 Nov; 55(21):4936-40. PubMed ID: 7585533
[TBL] [Abstract][Full Text] [Related]
19. A Chemical Proteomic Analysis of Illudin-Interacting Proteins.
Le P; Nodwell MB; Eirich J; Sieber SA
Chemistry; 2019 Sep; 25(54):12644-12651. PubMed ID: 31310394
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of illudin S, a toxic principle of Lampteromyces japonicus, by rat liver. I. Isolation and identification of cyclopropane ring-cleavage metabolites.
Tanaka K; Inoue T; Kadota S; Kikuchi T
Xenobiotica; 1990 Jul; 20(7):671-81. PubMed ID: 2238702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
